Under the collaboration, the Max Planck Institute will conduct a series of influenza virus growth studies to determine the advantages of Biovest’s proprietary Hollow Fiber Bioreactor Systems for the efficient and cost-effective cell culture manufacture of viral vaccines.
The organizations will also work on optimizing the conditions for efficient virus production and demonstrate large-scale manufacturing potential.
Biovest chief science officer Mark Hirschel said the collaboration with Max Planck would further demonstrate the advantages and viability of hollow fiber perfusion technology as robust, modular and rapid response instrumentation for the large scale production of viral vaccines.
The financial terms of the deal have not been revealed.